Journal of Neuro-Oncology

, Volume 103, Issue 1, pp 147–153

Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors

  • Vita Ridola
  • Giuseppe Barone
  • Ilaria Lazzareschi
  • Antonio Ruggiero
  • Daniela Rizzo
  • Riccardo Riccardi
Clinical Study – Patient Study

Abstract

Temozolomide (TMZ) is an oral alkylating agent with proven antitumoral activity in preclinical and clinical studies in adults with high-grade glioma (HGG). However, only limited efficacy has been reported in children with HGG using the 5-day schedule. This study investigated the safety of administering TMZ to children and adolescents with brain tumors over an extended period. Extended schedules have been proven to overcome chemoresistance without any major toxicity. The toxicity of TMZ, administered at 70 mg/m2/day orally for 21 consecutive days every 28 days, was assessed in children with brain tumors. A total of 156 courses of TMZ were given to 17 patients (median age 12.5 years, range 1–17 years), who were recruited into the study. Eleven patients had progressive or relapsing disease, and six patients were newly diagnosed. In this cohort no cases of toxic death or nonhematological toxicity were reported. In comparison with the 5-day schedule, thrombocytopenia and neutropenia were noted to be less frequent. Grades 3 and 4 lymphopenia occurred in 10.8 and 22.4% of courses, respectively; among the lymphopenic patients there was one case of disseminated zoster (meningoencephalitis and cutaneous involvement), one case of rotavirus gastroenteritis, and two cases of herpetic stomatitis reported. The objective response rate was 11.8%. Overall, 82.3% of patients showed stable disease. The prolonged TMZ schedule appeared to be well tolerated, with few cases of neutropenia or thrombocytopenia recorded. Nevertheless, prolonged exposure to TMZ was associated with lymphopenia and may lead to a higher rate of viral infections.

Keywords

Brain tumors Temozolomide Prolonged low-dosage schedule Lymphopenia 

References

  1. 1.
    Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS (1992) Phase I trial of temozolomide. Br J Cancer 65:287–291PubMedCrossRefGoogle Scholar
  2. 2.
    Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771PubMedGoogle Scholar
  3. 3.
    Lashford LS, Thiesse P, Jouvet A et al (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom children’s cancer study group and French society for pediatric oncology intergroup study. J Clin Oncol 20:4684–4691PubMedCrossRefGoogle Scholar
  4. 4.
    Verschuur AC, Grill J, Vassal G et al (2004) Temozolomide in pediatric high-grade glioma: a key for combination therapy ? Br J Cancer 91:425–429PubMedCrossRefGoogle Scholar
  5. 5.
    Kuo DJ, Weiner HL, Wisoff J, Miller DC, Knopp EA, Finlay JL (2003) Temozolomide is active in childhood, progressive unresectable, low-grade gliomas. J Pediatr Hematol Oncol 25:372–378PubMedCrossRefGoogle Scholar
  6. 6.
    Khaw SL, Coleman LT, Downie PA, Heath JA, Ashley DM (2007) Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer 49:808–811PubMedCrossRefGoogle Scholar
  7. 7.
    Nicholson HS, Kretschmar CS, Krailo M et al (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children’s Oncology Group. Cancer 110:1542–1550PubMedCrossRefGoogle Scholar
  8. 8.
    Wick W, Platten M, Weller M (2009) New (alternative) temozolomide regimens for the treatment of glioma. Neuro-Oncology 11:69–79PubMedCrossRefGoogle Scholar
  9. 9.
    Kong DS, Lee JI, Kim WS et al (2006) A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16:1117–1121PubMedGoogle Scholar
  10. 10.
    Kesari S, Schiff D, Drappatz J et al (2009) Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15:330–337PubMedCrossRefGoogle Scholar
  11. 11.
    Tolcher AW, Gerson SL, Denis L et al (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004–1011PubMedCrossRefGoogle Scholar
  12. 12.
    Bertolini F, Paul S, Mancuso P et al (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342–4346PubMedGoogle Scholar
  13. 13.
    Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195–1206PubMedGoogle Scholar
  14. 14.
    Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM (2007) Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther 321:265–275PubMedCrossRefGoogle Scholar
  15. 15.
    Virrey JJ, Golden EB, Sivakumar W et al (2009) Glioma-associated endothelial cells are chemoresistant to temozolomide. J Neurooncol 95:13–22PubMedCrossRefGoogle Scholar
  16. 16.
    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  17. 17.
    http://ctep.cancer.gov/forms/CTCAE.pdf. Accessed January 1, 2004
  18. 18.
    Sterba J, Pavelka Z, Slampa P (2002) Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 49:117–120PubMedGoogle Scholar
  19. 19.
    Su YB, Sohn S, Krown SE et al (2004) Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22:610–616PubMedCrossRefGoogle Scholar
  20. 20.
    Ruggiero A, Cefalo G, Garré ML et al (2006) Phase II trial of temozolomide in children with recurrent high-grade glioma. J Neurooncol 77:89–94PubMedCrossRefGoogle Scholar
  21. 21.
    Brock CS, Newlands ES, Wedge SR et al (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363–4367PubMedGoogle Scholar
  22. 22.
    Khan RB, Raizer JJ, Malkin MG et al (2002) A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncology 4:39–43PubMedGoogle Scholar
  23. 23.
    Stupp R, Dietrich P, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382PubMedCrossRefGoogle Scholar
  24. 24.
    Ganière V, Christen G, Bally F et al (2006) Listeria brain abscess, Pneumocystis pneumonia and Kaposi’s sarcoma after temozolomide. Nat Clin Pract Oncol 3:339–343PubMedCrossRefGoogle Scholar
  25. 25.
    Baruchel S, Diezi M, Hargrave D et al (2006) Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 42:2335–2342PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Vita Ridola
    • 1
  • Giuseppe Barone
    • 1
  • Ilaria Lazzareschi
    • 1
  • Antonio Ruggiero
    • 1
  • Daniela Rizzo
    • 1
  • Riccardo Riccardi
    • 1
  1. 1.Department of Pediatric Oncology, A. Gemelli HospitalCatholic University of RomeRomeItaly

Personalised recommendations